Lafutidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lafutidine
Lafutidine.png
Systematic (IUPAC) name
2-[(2-furylmethyl)sulfinyl]-N-((2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy}but-2-en-1-yl)acetamide
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Routes Oral
Identifiers
CAS number 118288-08-7 YesY
ATC code A02BA08
PubChem CID 5282136
ChemSpider 4445337 N
UNII 49S4O7ADLC YesY
KEGG D01131 YesY
Chemical data
Formula C22H29N3O4S 
Mol. mass 431.54 g/mol
 N (what is this?)  (verify)

Lafutidine (INN) is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use[edit]

Lafutidine is used to treat gastric ulcers, duodenal ulcers, stomal ulcers, wounds in the lining of the stomach associated with acute gastritis and with acute exacerbation of chronic gastritis.[1][2]

Adverse effects[edit]

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea or vomiting and dizziness.[2]

Mechanisms of action[edit]

Like other H2 receptor antagonists it prevents the secretion of gastric acid.[2] It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.[2]

History[edit]

It is marketed in Japan as Stogar by UCB[1] and in India as Lafaxid by Zuventus Healthcare.[2]

References[edit]

  1. ^ a b UCB Japan Revised: April 2005 Stogar tablets
  2. ^ a b c d e Zuventus Healthcare Ltd. India Lafaxid tablets